These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 7768266)

  • 1. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells.
    Van de Kar LD; Javed A; Zhang Y; Serres F; Raap DK; Gray TS
    J Neurosci; 2001 May; 21(10):3572-9. PubMed ID: 11331386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.
    Li Q; Rittenhouse PA; Levy AD; Alvarez Sanz MC; Van de Kar LD
    Neuropharmacology; 1992 Oct; 31(10):983-9. PubMed ID: 1359439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion.
    Vicentic A; Li Q; Battaglia G; Van de Kar LD
    Eur J Pharmacol; 1998 Apr; 346(2-3):261-6. PubMed ID: 9652368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499).
    Van de Kar LD; Levy AD; Li Q; Brownfield MS
    Pharmacol Biochem Behav; 1998 Jul; 60(3):677-83. PubMed ID: 9678651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo.
    Gartside SE; Cowen PJ; Hjorth S
    Eur J Pharmacol; 1990 Dec; 191(3):391-400. PubMed ID: 1964908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors.
    Kidd EJ; Haj-Dahmane S; Jolas T; Lanfumey L; Fattaccini CM; Guardiola-Lemaitre B; Gozlan H; Hamon M
    J Pharmacol Exp Ther; 1993 Feb; 264(2):863-72. PubMed ID: 8094756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine profile of the potential anxiolytic drug S-20499.
    Levy AD; Li Q; Gustafson M; Van de Kar LD
    Eur J Pharmacol; 1995 Feb; 274(1-3):141-9. PubMed ID: 7768266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the neuroendocrine role of serotonin.
    Jørgensen HS
    Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT neuroendocrine responses during psychotropic drug treatment: an investigation of the effects of lithium.
    Cowen PJ; Cohen PR; McCance SL; Friston KJ
    J Neurosci Methods; 1990 Sep; 34(1-3):201-5. PubMed ID: 2259242
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.